Remimazolam and Propofol

Phase 3Small molecule

DDan Liu

Remimazolam and Propofol is one of 3 small molecule programs targeting Remimazolam. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RemimazolamActive, not recruiting

RemimazolamPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Remimazolam

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

16 2

Remimazolam and Propofol

DDan Liu

Phase 3

1 3

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Remimazolam1 trial

Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy

Active, not recruiting·DDan Liu·Phase 4·NCT06784479·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Remimazolam and Propofol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remimazolam and Propofol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remimazolam and Propofol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dan Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDan Liu

Remimazolam and Propofol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Remimazolam1 trial

References

Drug Info

Quick Facts

Related News